AbCellera Biologics Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Carl Hansen
- Full Time Employees
- 562
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 150 W 4th Ave Vancouver BC Canada V5Y 1G6
- IPO Date
- Dec 11, 2020
- CIK
- 0001703057
- Website
- abcellera.com
- Similar Companies
- Business
- AbCellera Biologics Inc. (ABCL) is a biotechnology company that discovers and develops antibody-based therapeutics using proprietary AI-powered platforms for target discovery, antibody discovery, and optimization. The company offers integrated services including de novo antibody discovery from immune cells; computational protein design and engineering; and GPCR and ion channel screening technologies, with key partnerships supporting programs in oncology, metabolic and endocrine conditions, and autoimmune diseases. AbCellera operates primarily in North America and Europe, serving pharmaceutical and biotechnology partners; it was founded in 2012 and is headquartered in Vancouver, Canada. Core products and services encompass the AbCellera Engine platform, which combines microfluidics, deep learning AI, and single-cell analysis for rapid antibody isolation; proprietary FC Sort and FC Nano technologies for high-throughput functional screening; and end-to-end development support from discovery to preclinical candidates, including bispecific antibodies and antibody-drug conjugates under brands like those partnered with Eli Lilly and Novartis. The company targets large-molecule therapeutics across immunology, neurodegeneration, and infectious diseases, with a pipeline featuring wholly-owned assets such as ABCL635 for metabolic disorders and partnered programs advancing in Phase 1 trials. In the last 1-2 years, AbCellera expanded its strategic alliances, including a major multi-target collaboration with AbbVie in 2024 for immunology and neuroscience antibodies; launched new proprietary programs like ABCL575 targeting T-cell mediated autoimmune diseases; and completed a $225 million strategic financing round in late 2024 led by existing partners to fuel internal pipeline advancement and AI platform enhancements. The company also advanced clinical milestones, with partner Eli Lilly dosing first patients in Phase 1 for bebtelovimab follow-ons and initiating new GPCR-focused discovery deals. These developments underscore AbCellera's shift toward balancing partner-funded discovery with owned clinical assets amid biotech market dynamics.
Company News
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of “Moderate Buy” from Analysts
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
BlackRock Inc. Makes New Investment in AbCellera Biologics Inc. $ABCL
What'sGoing On With AbCellera Biologics Stock On Tuesday?
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
What's Going on With AbCellera Biologics Stock On Wednesday?
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Investors Buy Large Volume of AbCellera Biologics Call Options (NASDAQ:ABCL)
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'
AbCellera Stock Jumps 33% on a Positive Menopause Trial
AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi
AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile